AstraZeneca presented key data on Farxiga (dapagliflozin) in diverse patient populations with type-2 and type-1 diabetes (T2D, T1D) at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Florida, 22-26 June 2018.
These studies reinforce the use of dapagliflozin as a treatment option to help improve glycaemic control when used with the DPP-4 inhibitor Onglyza (saxagliptin) vs. older treatment options (insulin, sulfonylurea) in patients with T2D. Data investigating the impact of dapagliflozin across patients with a spectrum of cardiovascular (CV) risks were also presented to help further the scientific understanding of the effects of SGLT-2 inhibitors (SGLT-2i) on CV events.
Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development, AstraZeneca said: “We are firmly committed to addressing the complex unmet needs of people affected by diabetes, of whom many have interrelated CV risks. Through our completed and ongoing research with Farxiga, we are proud to have developed a highly representative clinical programme that we believe will help change clinical practice where there remains a need for earlier and more aggressive treatment approaches with SGLT-2 inhibitors.”